Strategic Partnership

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to Access mRNA Technologies

eTheRNA Immunotherapies NV

Emergency Response

Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response

Merck & Co.

CRISPR

MilliporeSigma Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology

MilliporeSigma

Awards

MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018

MilliporeSigma

Patient Adherence

Medisafe Partners with Merck KGaA, Darmstadt, Germany to Improve Adherence for Patients with Cardiometabolic Disorders in Russia, Mexico and Brazil

Medisafe

Granted Designation

Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1

Merck & Co.

Approval

Merck Receives Recommendation for Approval in 21 EU Countries for the New Formulation of Euthyrox®

Merck & Co.

Therapy Approval

KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Merck & Co.

HIV Therapy

Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine

Merck & Co.

Trial Results

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

MilliporeSigma

Collaboration

Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection

Merck & Co.

Collaboration

Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck

Foundation Medicine

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival for Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck & Co.

Clinical Trials

Merck Provides Update on KEYNOTE-407 Trial

Merck & Co.